Haldol (Haloperidol)

Haloperidol is prescribed for several psychiatric disorders where dopamine dysregulation is implicated.

• Schizophrenia, including maintenance therapy for chronic illness.
• Acute psychotic episodes, such as those related to substance intoxication or withdrawal.
• Manic episodes associated with bipolar disorder when rapid control of agitation is needed.
• Tourette syndrome, particularly for reducing motor and vocal tics.
• Severe agitation or aggression in hospital settings when other measures are insufficient.
• Adjunctive treatment for severe anxiety disorders when standard therapies have failed.

Like other typical antipsychotics, haloperidol may cause a range of neurological and non‑neurological effects.

Common

• Drowsiness or sedation.
• Dry mouth and increased thirst.
• Constipation or reduced gastrointestinal motility.
• Extrapyramidal symptoms such as mild tremor, rigidity, or akathisia.
• Blurred vision or difficulty focusing.

Serious

• Tardive dyskinesia, characterized by involuntary, repetitive movements.
• Neuroleptic malignant syndrome, a life‑threatening reaction with fever and muscle rigidity.
• Severe hypotension or cardiac arrhythmias.
• Elevated prolactin levels leading to galactorrhea or menstrual disturbances.
• Seizures, particularly in patients with a history of epilepsy.
• Persistent or worsening extrapyramidal symptoms requiring medical intervention.

Clinicians should evaluate patient history and monitor for specific risks before and during haloperidol therapy.

• History of cardiovascular disease, as haloperidol can affect heart rhythm.
• Pre‑existing movement disorders, which may be worsened by extrapyramidal side effects.
• Liver or kidney impairment, which may alter drug clearance.
• Pregnancy or breastfeeding status, because safety data are limited.
• Elderly patients, especially those with dementia, who have higher sensitivity to sedation and falls.
• Concomitant use of other dopamine‑blocking agents, increasing risk of severe side effects.

Haloperidol interacts with several medication classes; awareness helps prevent adverse events.

Avoid

• Other antipsychotics or dopamine antagonists, which can amplify extrapyramidal effects.
• Drugs that prolong the QT interval, such as certain antiarrhythmics or macrolide antibiotics.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) that raise haloperidol plasma levels.

Use with caution

• CNS depressants, including benzodiazepines and opioids, due to additive sedation.
• Anticholinergic agents, which may mask early signs of extrapyramidal symptoms.
• Lithium, because combined use can increase neurotoxicity risk.
• Antihypertensive medications, as haloperidol may cause orthostatic hypotension.